Noom's GLP-1 programme is advertised at "starting at $79", with the standard tier at $129, both described as including the medication and needing no insurance. Those are the numbers in the banner, on the plan cards, and in the summary at the top of Noom's own pricing article.
The footnote underneath describes something else.
Every figure here was read from noom.com on 2026-09-09. This page reports published prices and terms; it does not recommend a medicine or a programme, as our editorial standards set out.
The footnote
Initial 3 week subscription and 4 weeks of medication from $99 plus tax and $199 per month plus tax for 12 week subscription thereafter. Final pricing depends on program selection. Includes medication (if prescribed) and full program access. Cancel anytime.
Read that sentence for its units. It contains a 3-week subscription, 4 weeks of medication, a rate per month, and a 12-week subscription. Four different time periods in one disclosure, and the number a reader carries away — $79, or $99 — is measured against the shortest of them while the number they will actually pay, $199 a month, is measured against the longest.
None of this is concealed; it is printed on the page. But an entry price quoted against a three-week subscription is not comparable with a monthly price from anywhere else, and the arithmetic only becomes visible if the asterisk is followed.
What the tiers are
Noom sells its GLP-1 care in a ladder, and the ladder is a quantity ladder.
| Programme | Advertised from | What Noom says it is |
|---|---|---|
| Noom Weight | $17.42/mo (12-month plan) | Behavioural programme, no medication |
| Noom Microdose GLP-1 Rx | $79 | "designed to offer a low dose compared to our standard GLP-1 plan" |
| Noom GLP-1 Rx / Rx Plus | $129 | "semaglutide or tirzepatide plan with SmartDose titration" |
| Noom Proactive Health Microdose GLP-1 Rx | — | "Noom's lowest-dose GLP-1" programme |
The cheapest medicated tier is the one with the least medicine in it. That is not a criticism — it is the honest consequence of pricing a product by how much of it is supplied — but it does mean a monthly figure from Noom carries no information on its own. Two people quoting a Noom price can be describing different quantities of a different molecule on a different billing cadence.
"Microdose" and "microdosing" are Noom's own product names. Neither word appears in the approved labelling of any GLP-1 medicine; approved products carry specific strengths and titration schedules, not a category by that name. The word here is doing commercial work, marking a cheaper tier.
The $17.42 is an annual price
The behavioural programme is advertised at $17.42 a month, which is a conspicuously precise number. It is precise because it is a division: Noom states that plans are "auto-renewing and billed up front, and the longer your commitment, the more you save per month."
$17.42 × 12 = $209.04, paid in advance, renewing automatically.
There is a seven-day trial and the page says cancel anytime, both of which are real. The monthly figure is simply the shape of an annual commitment rather than a monthly charge, and it contains no medication at all — it is the psychology-and-tracking programme, which is what Noom was before it had a pharmacy attached.
The disclosure Noom gets right
One thing on this page is better than most of the category, and it should be said plainly.
Compounded semaglutide available through Noom-GLP1ᴿˣ is produced in an FDA-registered facility but has not been reviewed by the FDA for safety, efficacy, or quality.
That sentence keeps two things apart that marketing in this space routinely blurs. An FDA-registered facility is a building that has registered with the agency. Registration is an administrative fact about premises. It says nothing about whether the medicine made there has been reviewed, and the phrase is frequently deployed in a way that invites readers to hear "FDA-approved". Noom states the registration and then states, in the same sentence, that the product has not been reviewed for safety, efficacy or quality. That is the correct construction and it is worth crediting.
The substance of it still matters for anyone comparing prices: the medicine in these programmes is a compounded preparation, not an approved product. The trial results that make GLP-1s worth wanting were generated with approved products under published protocols. There is no equivalent evidence for any compounded preparation, because compounded preparations are not studied as products.
What Noom does not make obvious
The advertised price and the ongoing price are different numbers on different clocks. $79 or $99 buys an initial short subscription; $199 a month is what the footnote attaches to the continuing one.
The cheap tier is cheap because it contains less drug. This is disclosed and logical, and it makes cross-provider price comparison close to meaningless without knowing the tier.
The medication is compounded. Disclosed clearly, but it changes what is being bought relative to any manufacturer price.
The comparison worth making
Against other telehealth providers, the question to settle first is always whether a quoted monthly figure contains a medicine and which kind. Some do and some do not — WeightWatchers charges $74 a month and excludes the drug entirely, while Mochi splits a membership fee from the medication price and the two halves live on different pages.
Against the branded products, the comparison is between categories rather than prices. The manufacturers' self-pay routes have come down a long way and carry conditions that change the real figure — those are set out on our GLP-1 cost page, with the brand-level terms for Zepbound, Wegovy, Mounjaro and Ozempic. What became of compounded semaglutide as a category, and what replaced it, is covered separately in what replaced it.